Author
Listed:
- Claus Niederau
- Stefan Mauss
- Andreas Schober
- Albrecht Stoehr
- Tim Zimmermann
- Michael Waizmann
- Gero Moog
- Stefan Pape
- Bernd Weber
- Konrad Isernhagen
- Petra Sandow
- Bernd Bokemeyer
- Ulrich Alshuth
- Hermann Steffens
- Dietrich Hüppe
Abstract
Background: Previous trials have often defined genotype 2 and 3 patients as an “easy to treat” group and guidelines recommend similar management. Aims: The present study looks for differences between the two genotypes and analyzes predictive factors for SVR. Methods: Prospective, community-based cohort study involving 421 physicians throughout Germany. The analysis includes 2,347 patients with untreated chronic HCV genotype 2 (n = 391) and 3 (n = 1,956) infection treated with PEG-IFN α-2a plus ribavirin between August 2007 and July 2012. Results: When compared with genotype 2 patients, those with genotype 3 were younger, had a shorter duration of infection, lower values of total cholesterol, LDL cholesterol and BMI, a higher frequency of drug use as infection mode and male gender (p 130 mg/dl, a low APRI score, and a γ-GT ≥3-times ULN, RVR, and RBV starting dose were associated with SVR by multivariate analysis. Conclusions: The present study corroborates that liver fibrosis is more pronounced in genotype 3 vs. 2. SVR is higher in genotype 2 versus genotype 3 partly because of follow-up problems in genotype 3 patients, in particular in those infected by drug use. Thus, subgroups of genotype 3 patients have adherence problems and need special attention also because they often have significant liver fibrosis. Trial Registration: Verband Forschender Arzneimittelhersteller e.V., Berlin, Germany ML21645 ClinicalTrials.gov NCT02106156
Suggested Citation
Claus Niederau & Stefan Mauss & Andreas Schober & Albrecht Stoehr & Tim Zimmermann & Michael Waizmann & Gero Moog & Stefan Pape & Bernd Weber & Konrad Isernhagen & Petra Sandow & Bernd Bokemeyer & Ulr, 2014.
"Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3,"
PLOS ONE, Public Library of Science, vol. 9(9), pages 1-10, September.
Handle:
RePEc:plo:pone00:0107592
DOI: 10.1371/journal.pone.0107592
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0107592. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.